Objective: In 2004, The American Chemistry Council Phosgene Panel established a phosgene exposure registry among US phosgene producers with the primary purpose of monitoring health outcome information for workers with acute exposure.
Methods: We examine symptoms among 338 workers with phosgene exposure. The phosgene exposures averaged 8.3 ppm-minutes ranging up to 159 ppm-minutes with most exposures below 10 ppm-minutes.
Results: We found that the level of phosgene exposure in ppm-minutes was related to workers reporting mostly irritation symptoms of the nose, throat and eyes within 48 hours of exposure. However, we found no relationship between phosgene exposure and the presence of symptoms 30 days after exposure.
Conclusions: These findings lend credence to the theory that prolonged respiratory effects do not occur with doses less than 150 ppm-minutes.
From the Dow Chemical Company (Drs Collins and Carson), Midland, Mich; Bayer Business and Technology Services, LLC (Dr Molenaar), Pittsburgh, Penn; SABIC Innovative Plastics (Mr Bowler), Mt Vernon, Ind; Huntsman Polyurethanes (Mr Harbourt), Geismar, La; Bayer CropScience Institute (Dr Avashia and Ms Calhoun), WVa; Occupational Physician (Dr Vitrano), Baton Rouge, La; VanDeMark (Mr Ameis), Lockport, New York; DuPont (Mr Chalfant), Wilmington, Del; and Chemtura (Mr Howard), El Dorado, Az.
Address correspondence to: James J. Collins, PhD, The Dow Chemical Company, 1803 Bldg, Midland, MI 48674; firstname.lastname@example.org.